Coya Therapeutics Inc. (COYA)
6.41
-0.15 (-2.29%)
At close: Apr 24, 2025, 3:59 PM
6.41
-0.01%
After-hours: Apr 24, 2025, 04:49 PM EDT
-2.29% (1D)
| Bid | 6 |
| Market Cap | 107.21M |
| Revenue (ttm) | 3.55B |
| Net Income (ttm) | -14.88M |
| EPS (ttm) | -0.98 |
| PE Ratio (ttm) | -6.54 |
| Forward PE | -4.35 |
| Analyst | Buy |
| Ask | 7 |
| Volume | 82,869 |
| Avg. Volume (20D) | 101,954 |
| Open | 6.83 |
| Previous Close | 6.56 |
| Day's Range | 6.32 - 6.91 |
| 52-Week Range | 4.65 - 10.24 |
| Beta | 0.50 |
About COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial f...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 29, 2022
Employees 8
Stock Exchange NASDAQ
Ticker Symbol COYA
Website https://www.coyatherapeutics.com
Analyst Forecast
According to 4 analyst ratings, the average rating for COYA stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 180.81% from the latest price.
Stock ForecastsNext Earnings Release
Coya Therapeutics Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+7.2%
Coya Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
5 months ago
-27.67%
Coya Therapeutics shares are trading lower. The company announced results from the placebo-controlled Phase 2 clinical trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease.
